Protective effect of pentraxin 3 on pathological retinal angiogenesis in an in vitro model of diabetic retinopathy

Arch Biochem Biophys. 2022 Aug 15:725:109283. doi: 10.1016/j.abb.2022.109283. Epub 2022 May 13.

Abstract

Background: Diabetic retinopathy (DR) is the most common retinal microvascular disease caused by diabetes. Previous studies indicated that Pentraxin 3 (PTX3), an acute phase reactant, was closely related to the development of DR. But the exact effect of PTX3 in diabetic retinopathy needs more investigations.

Methods: Real-time fluorescence quantitative polymerase chain reaction (qRT-PCR) analysis and western blot (WB) were used to detect the expression of PTX3 in vitro. The Ki67 immunofluorescent staining, scratch-wound migration assay, and tube formation experiments were performed to detect the effect of PTX3 knockdown and overexpression on the fibroblast growth factor (FGF)-induced proliferation, migration and tube-forming ability of human retinal microvascular endothelial cells (HRMECs). The phosphorylation levels of extracellular regulated protein kinases (ERK) and fibroblast growth factor receptor (FGFR) in HRMECs were detected by WB.

Results: In vitro, the mRNA and protein expressions of PTX3 in the high-concentration glucose condition group were upregulated compared with the normal group (p < 0.05). The proliferation, migration and tube-forming abilities of HRMECs exposed to high-concentration glucose were enhanced (p < 0.01, p < 0.01, p < 0.05 respectively), and the phosphorylation of FGFR and ERK1/2 were increased (p < 0.01, p < 0.05 respectively) compared with the normal condition group. Compared with the high glucose condition group, the proliferation, migration and tube-forming abilities of HRMECs in the high glucose + PTX3 siRNA condition group were further strengthened (p < 0.001, p < 0.0001, p < 0.05 respectively), and the phosphorylation of FGFR and ERK1/2 were increased (p < 0.001, p < 0.01 respectively). Compared with the high glucose condition group, the proliferation, migration and tube-forming abilities of HRMECs in the high glucose + PTX3 overexpression condition group were compromised (p < 0.001, p < 0.05, p < 0.01 respectively), and the phosphorylation of FGFR and ERK1/2 were inhibited (p < 0.001, p < 0.0001 respectively). Neither the scramble siRNA condition group nor the blank plasmid condition group showed significant difference on the proliferation, migration and tube-forming abilities of HRMECs compared with the high glucose condition group (p > 0.05).

Conclusions: The upregulated expression of PTX3 may play a protective role on pathological angiogenesis in DR. PTX3 may serve as a new target for the treatment of DR.

Keywords: Angiogenesis; Diabetic retinopathy; Pentraxin 3.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • C-Reactive Protein* / biosynthesis
  • C-Reactive Protein* / genetics
  • Cell Proliferation
  • Diabetes Mellitus / metabolism
  • Diabetes Mellitus / pathology
  • Diabetic Retinopathy* / metabolism
  • Diabetic Retinopathy* / pathology
  • Endothelial Cells / metabolism
  • Glucose / metabolism
  • Glucose / pharmacology
  • Humans
  • MicroRNAs* / genetics
  • MicroRNAs* / metabolism
  • Neovascularization, Pathologic / metabolism
  • Neovascularization, Pathologic / pathology
  • RNA, Messenger / genetics
  • RNA, Messenger / metabolism
  • RNA, Small Interfering / genetics
  • RNA, Small Interfering / metabolism
  • Serum Amyloid P-Component* / biosynthesis
  • Serum Amyloid P-Component* / genetics
  • Up-Regulation

Substances

  • MicroRNAs
  • RNA, Messenger
  • RNA, Small Interfering
  • Serum Amyloid P-Component
  • PTX3 protein
  • C-Reactive Protein
  • Glucose